retatrutide clinical trial brazil for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational trials 💉 A triple-action once-weekly injection

And our current thinking about obesity, and one of the components of the disease of obesity, is that some individuals although they all have GLP-1 and these other gut hormones, amylin, glucagon, GIP, that's what they're called that signal, for some reason, is not getting to the brain in ample amounts to tell the individual to feel full, satiated, and stop eating

Forebrain networks and the control of feeding by environmental learned cues

Our results propose that DIV-1 may control the level of threshold for GLP-1/Notch-mediated germline proliferation

The logic is that full therapeutic doses cause appetite suppression so dramatic that maintaining the caloric intake needed for training becomes nearly impossible